|
- Branch Retinal Vein Occlusion - University of Iowa
The 2010 Branch Retinal Vein Occlusion (BRAVO) study examined the outcomes of intravitreal anti-VEGF injections for treatment of BRVO [12] In this randomized, sham injection-controlled clinical trial, patients with BRVO-associated CME received intraocular injections of 0 3 mg or 0 5 mg ranibizumab (Lucentis®)
- Symptomatic Branch Retinal Artery Occlusion: An Under-Recognized Sign . . .
Symptomatic Branch Retinal Artery Occlusion: An Under-Recognized Sign of Stroke, Ophthalmology Case Reports and Grand Rounds from the University of Iowa Department of Ophthalmology Visual Sciences
- EyeRounds. org: Acute Onset of Unilateral Trochleitis
Acute Onset of Unilateral Trochleitis Ophthalmology Case Reports and Grand Rounds from the University of Iowa Department of Ophthalmology Visual Sciences
- JLA FORUMS - FOR SALE - Amarillo, TX
Subject: 2007 Stingray 250 CR with MerCruiser 350 MAG Bravo III drive (Amarillo) $11,500
- EyeRounds. org: central retinal artery occlusion (CRAO)
Discussion The patient’s classic description of painless, sudden loss of vision one day prior to presentation, and the appearance of the "cherry-red spot" on fundus examination made the diagnosis of a central retinal artery occlusion (CRAO) This elderly patient had a history of coronary artery disease s p bypass surgery as well as carotid vascular disease treated with an endartectomy on the
- Atlas Entry - Optociliary shunt vessels - University of Iowa
This 87-year-old male has alongstanding history of primary open angle glaucoma His optic nerve is significantly cupped with a marked number of optociliary shunt vessels There are several drusen in the peripapillary region Optociliary shunt vessels are collateral vessels connecting the choroidal and the retinal vasculature The differential diagnosis for acquired optociliary shunt vessels
- FOR SALE - Chicago, IL - JLA FORUMS
All times are GMT - 4 Hours Things for sale in the Chicago, Illinois area
- 0. $*)
with BRVO-associated CME The later report focused on whether laser photocoagulation could prevent the development of N nsion of the BRAVO trial The RETAIN trial was the 49-month open-label ext d as a series of reports The SCORE Trial information in this table refers
|
|
|